QIAGEN NV to acquire Cellesis Limited
QIAGEN NV has reached an agreement to acquire Cellestis Limited for approximately AU$341 million in cash, providing QIAGEN with access to a novel ‘pre-molecular’ technology that offers a new dimension in disease detection not currently possible with other diagnostic methods.
The acquisition of Cellestis will provide QIAGEN with exclusive rights to QuantiFERON technology, a proprietary approach for disease detection and monitoring.
QuantiFERON is complementary to QIAGEN’s portfolio of molecular diagnostics. Its high sensitivity and ability to provide clinically relevant information means that this technology can be used ahead of DNA- or RNA-based molecular testing. Greater use of QuantiFERON technology can help guide and drive the use of traditional DNA- and RNA-based molecular diagnostics.
Govt and industry fund health and biotech innovation in SEQ
The SEQ Innovation Economy Fund has awarded eight projects $94m in government funding, while...
Does the 2025–26 Budget do enough for science?
AAMRI has described the 2025–26 federal Budget as "very disappointing" for the...
Ming Long appointed Chair of CSIRO
Minister for Industry and Science Ed Husic has announced the appointment of Ming Long to the role...
